Two respiratory viruses, one antibody

Humabs BioMed S.A. and the Institute for Research in Biomedicine at the University of Lugano have identified an antibody that could offer multiple advantages over the blockbuster respiratory syncytial virus prophylactic Synagis palivizumab. The group expects that their product, MPE8, could be used to both treat and prevent respiratory syncytial virus. It also could be effective against metapneumovirus, another common respiratory virus.¹

Respiratory syncytial virus (RSV) and metapneumovirus (MPV) both can cause severe disease in premature newborns, hospitalized children and immune-compromised adults.^2-5...